- 1 Research note
2
- 2

³**Performance of an artificial intelligence-based smartphone app for guided reading** ⁴**of SARS-CoV-2 lateral-flow immunoassays**

-
- 5 6 David Bermejo-Peláez^{*1}
7 Daniel Marcos-Mencía^{*2}
- 7 Daniel Marcos-Mencía^{*2}
8 Elisa Álamo¹
- 8 Elisa Álamo¹
9 Nuria Pérez-F
- 9 Nuria Pérez-Panizo³
10 Adriana Mousa¹
- 10 Adriana Mousa¹
11 Elena Dacal¹
- 11 Elena Dacal¹
12 Lin Lin^{1,4}
-
- 12 $\text{Lin Lin}^{1,4}$
13 Alexander 13 Alexander Vladimirov¹
14 Daniel Cuadrado¹
-
- 14 Daniel Cuadrado¹
15 Jesús Mateos-Noz
- 15 Jesús Mateos-Nozal³
16 Juan Carlos Galán^{2,5}
- 16 Juan Carlos Galán^{2,5}
17 Beatriz Romero-Herr 17 Beatriz Romero-Hernández^{2,5}
18 Rafael Cantón^{2,6}
-
- 18 Rafael Cantón^{2,6}
19 Miguel Luengo-19 Miguel Luengo-Oroz^{#1}
20 Mario Rodríguez-Dom
- 20 Mario Rodríguez-Domínguez^{#2,5} 21
-
- 22 22 $^{*,\#}$ Contributed equally
- 23
24
- 24 ¹Spotlab. Madrid, Spain
25 ²Servicio de Microbiolog
- 25 ²Servicio de Microbiología. Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid Spain
- 26 y Cajal de Investigación Sanitaria (IRYCIS). Madrid, Spain
27 ³ Servicio de Geriatría. Hospital Universitario Ramón y C
- ³ 3 ³ Servicio de Geriatría. Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid Spain
- 28 Cajal de Investigación Sanitaria (IRYCIS). Madrid, Spain
29 ⁴Biomedical Image Technologies, ETSI Telecomunicació
- ⁴Biomedical Image Technologies, ETSI Telecomunicación, Universidad Politécnica de Madrid & CIBER-BBN Madrid Spain
- 30 Madrid & CIBER-BBN. Madrid, Spain
31 ⁵CIBER en Epidemiología y Salud Púb
- ⁵ SCIBER en Epidemiología y Salud Pública (CIBERESP). Instituto de Salud Carlos III.
32 Madrid Spain
- 32 Madrid, Spain
33 ⁶CIBER en Er
- ⁶ 33⁶ CIBER en Enfermedades Infecciosas (CIBERINFEC). Instituto de Salud Carlos III.
34 Madrid Spain
- 34 Madrid, Spain
35
-
- 35
- 37
- 38 38 Corresponding author: Miguel Luengo-Oroz
39 miguel@spotlab.ai
- 39 miguel@spotlab.ai
40 Spotlab
-
- 40 Spotlab
41 Paseo Ju
- 41 Paseo Juan XXIII, 36B
42 28040, Madrid, Spain ⁴²28040, Madrid, Spain

Abstract

18 facilitate reporting of positive RDTs to relevant health authorities.

¹**Introduction**

²To control COVID-19 pandemic, timely and accurate early-detection strategies of ³SARS-CoV-2 infections have been critical to slow down the spread of the virus. The ⁴use of rapid diagnostic tests (RDTs), both for detection of antibodies and antigens, has 5 contributed to improve COVID-19 testing capacity reducing costs of diagnosis and ⁶allowing for fastest results (1). First, COVID-19 RDTs were intended to be used just by ⁷professional healthworkers, who have extensive experience in the use of this tool for 8 different infectious diseases (2, 3). Later, multiple Health Ministries have approved ⁹home testing kits improving the accessibility to testing and taking pressure off from 10 health institutions. Nevertheless, self-testing strategies have some limitations, the 11 general population is not familiar with the use of RDTs and a minimum training is 12 needed for sampling, testing and result interpretation. Furthermore, as it has been seen 13 during the latest Omicron wave (4), many results go unreported, impairing post-testing 14 counseling and epidemiological surveillance.

¹⁵Combining RDTs with digital tools, artificial intelligence (AI) and mobile health ¹⁶approaches can help standardize result interpretation and facilitate immediate reporting 17 and monitoring of results (5). The use of AI to automatically interpret photographs of ¹⁸RDTs has been also recently proposed (6, 7). Here, we describe the development and ¹⁹field validation of a mobile-based tool for reading and reporting multiple types of 20 SARS-COV-2 RDTs which is connected to a real-time epidemiological monitoring web 21 platform.

22

²³**Methods**

²⁴This study was divided into two phases. First, the training and validation of an AI 25 algorithm for the automatic interpretation of RDTs. Second, two field studies to assess

1 the performance of the AI-based system for reading both COVID-19 antibodies and ²antigen RDTs in real-world scenarios. Ethics approval for the study was obtained from 3 the Clinical Research Ethics Committee of the Ramón y Cajal University Hospital (Ref. ⁴127/21).

⁶*Algorithm Training and validation dataset*

⁷For generating the training image dataset, twelve human sera from SARS-CoV-2 8 positive PCR patients with a positive ELISA test (Vircell Spain S.L.U., Granada, Spain) ⁹were used. Each serum sample was serially diluted until it reached a negative result ¹⁰when inoculated in a COVID-Ab test. Each dilution was tested in three replicates for 11 each of the three brands tested (2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou 12 AllTest Biotech Co., Ltd.); Panbio COVID-19 IgG/IgM Rapid Test Device (Abbott); ¹³UNscience COVID-19 IgG/IgM Rapid Test (Wuhan UNscience Biotechnology Co., 14 Ltd.), resulting in 433 RDTs inoculated (61 IgG+/IgM+; 166 IgG+/IgM-; 43 IgG-¹⁵/IgM+; 164 negative). Additionally, twelve COVID-Ag RDTs (Panbio COVID-19 Ag 16 Rapid Test Device (Abbott) $(6+,6-)$ were also included to train the algorithm to read not 17 only three-band tests (such as the COVID-19 antibody tests used in this study) but also 18 two-band RDTs such as COVID-19 antigen tests. The entire training dataset consisted 19 of 3614 images.

²⁰For collecting the independent validation dataset, 240 human sera samples 21 independent from the ones used for training were used to inoculate 720 COVID-Ab ²²RDTs (each serum was tested in triplicate using the aforementioned brands). The ²³samples were selected ensuring all possible results are well represented along the 24 dataset (108 IgG+/IgM+; 321 IgG+/IgM-; 27 IgG-/IgM+; 264 negative).

Each RDT was visually read by multiple observers (from 3 to 5) and the ground truth was established as the majority result from the total of analyzers. Each inoculated RDT was digitized by using the TiraSpot mobile app (Spotlab, Madrid, Spain) for guided and standardized acquisition ensuring correct positioning of RDTs in the image and using a 5 total of 9 smartphone models. Results data was uploaded to a web platform.

⁷*Field validation studies*

8 The workflow for the field studies was as follows: a health professional digitized the ⁹RDTs by using the app, was asked for recording the visual interpretation of the test 10 result, images were uploaded to the telemedicine platform and processed by the AI ¹¹algorithm, and discrepancies between the interpretation made by the health professional 12 and that obtained by the algorithm were subsequently reviewed by an external health 13 professional through the platform.

14 The first field study used the system as part of a seroprevalence study conducted in 15 two nursing homes in Madrid (Spain). A total of 172 vaccinated health care personnel ¹⁶were included in this study from which a finger-prick blood sample was taken and 17 inoculated into SARS-CoV-2 Rapid Antibody Test (Roche). A trained nurse digitized 18 the RDTs and record their result using the application.

19 The second field validation field study tested the system to read also COVID-19 20 antigen tests composed of two bands (Panbio COVID-19 Ag Rapid Test Device, ²¹Abbot). This study was carried out at the Emergency Department of the Ramón y Cajal 22 Hospital (Madrid, Spain), where 92 individuals' nasal swabs were inoculated in antigen 23 tests, and digitized by experienced health professionals using the app.

²⁴All images were acquired in very diverse real-world conditions (including different 25 environmental illuminations and shades).

²**Results**

³*AI algorithm training and app validation*

All images acquired with the app were uploaded to a cloud platform where the AI algorithm processed the photographs to predict its result interpretation. As shown in **Table 1A**, when comparing the visual interpretations (used as ground truth) against the AI algorithm, the performance was high for all brands of RDTs tested, obtaining a mean 8 sensitivity and specificity of 98% and 100% respectively for detecting the IgG band and a mean sensitivity and specificity of 80% and 89% for the detection of the IgM band.

¹¹*Validation in real-world scenarios*

12 From the 172 RDTs used in this study $(5 \lg G + / \lg M + ; 149 \lg G + / \lg M + ; 17 \lg G - / \lg M + ; 17$ 13 negative), we only found 9 discrepancies between test result interpretation made by the 14 health professional and the AI algorithm. From these 9 cases, two of them were ¹⁵incorrectly classified by the algorithm due to an incorrect image acquisition with the ¹⁶app. The remaining discrepant cases were further reviewed by a second professional, 17 and the AI-based system allowed to detect and modify the result with respect to the 18 initial healthworker interpretation in 4 cases by confirming the result predicted by the 19 algorithm.

20 The overall performance of the algorithm with respect to the ground truth is shown in ²¹**Table 1B**. It should be noted that the performance of the system is high even when used 22 with a RDT different from those used for training the algorithm, suggesting its potential 23 use with any RDT on the market. The slight disparity in the performance of IgM band 24 identification in antibody RDTs between the validation set and this field study may be

¹explained by the presence of very faint signals which were almost invisible in the 2 photographs.

Regarding the second field study for reading COVID-19 antigen RDTs, we found that all tests used and digitized using the TiraSpot app (58 negative, 30 positive) were correctly interpreted by the proposed system (**Table 1C**), demonstrating that the system can also be applied for reading two-band (control and test) as well as three-band tests (IgG, IgM and control).

⁹**Discussion**

We describe the usefulness of an app for reading and result interpretation of lateral-flow RDTs for SARS-CoV-2 testing. Additionally, results are sent to a telemedicine platform which allows for case identification and confirmation, quality control and real-time 13 monitoring.

¹⁴Our AI algorithm demonstrates excellent performance, especially in prospective 15 validation in real-life scenarios and for both antibodies and antigen detection tests. The ¹⁶algorithm performed as well in RDTs brands which were not used at all for training 17 purposes, making the solution suitable for other RDTs, including other diseases. ¹⁸Compared with previous studies (6, 7), our system is able to identify individual bands of 19 the RDTs allowing complex results reading and sending them in real-time to a cloud 20 platform. A requirement and limitation of the proposed system is the correct acquisition 21 of the image (acquisition error in the field studies $\langle 0.8\% \rangle$.

22 In conclusion, the use of TiraSpot (**Figure 1**) is a useful tool for reporting, real-time 23 monitoring and quality control, as the results can be reviewed by specialists when ²⁴needed. This is especially important in contexts where massive testing is to be done and 25 the likelihood of subjectivity and errors in the interpretation of the result is higher. It is

- ¹also important in the validation of self-diagnostic tests performed by untrained users, as
- 2 it avoids the loss of information in case it is not notified by the user and provides an
- ³efficient system to confirm and report data, which has been a key challenge during the
- 4 Omicron wave (4).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.02.16.22271042;](https://doi.org/10.1101/2022.02.16.22271042) this version posted February 19, 2022. The copyright holder for this preprint

- **REFERENCES** 1. European Centre for Disease Prevention and Control. Options for the use of rapid antigen detection testsfor COVID-19 in the EU/EEA – first update, 26 October 2021. Stockholm: ECDC; 2021.
- 2. Weber NC, Klepser ME, Akers JM, Klepser DG, Adams AJ. Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States. Expert Rev Mol Diagn. 2016;16(2):253-64. doi: 10.1586/14737159.2015.1116388. Epub 2015 Nov 27. PMID: 26560318.
- 3. Bell SFE, Lemoire J, Debattista J, Redmond AM, Driver G, Durkin I, Coffey L, Warner M, Howard C, Williams OD, Gilks CF, Dean JA. Online HIV Self-Testing (HIVST) Dissemination by an Australian Community Peer HIV Organisation: A Scalable Way to Increase Access to Testing, Particularly for Suboptimal Testers. *International Journal of Environmental Research and Public Health*. 2021; 18(21):11252. https://doi.org/10.3390/ijerph182111252
- 4. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao NY, Korsman S, Davies MA, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenço J, Alcantara LCJ, Kosakovsky Pond SL, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021 Apr; 592(7854):438-443. doi: 10.1038/s41586-021- 03402-9. Epub 2021 Mar 9. PMID: 33690265.
- 5. Kadam R, White W, Banks N, Katz Z, Dittrich S, Kelly-Cirino C. Target Product Profile for a mobile app to read rapid diagnostic tests to strengthen infectious disease surveillance. PLoS One. 2020 Jan 29; 15(1):e0228311. doi: 10.1371/journal.pone.0228311. PMID: 31995628; PMCID: PMC6988927.Mendels
- 6. Turbé, V., Herbst, C., Mngomezulu, T. *et al.* Deep learning of HIV field-based rapid tests. *Nat Med* **27,** 1165–1170 (2021). https://doi.org/10.1038/s41591-021-01384-9
- 7. David-A. Mendels, Laurent Dortet and Cécile Emeraud et al. Using artificial intelligence to improve COVID-19 rapid diagnostic test result interpretation. Proceedings of the National Academy of Sciences of the United States of America. Vol. 118(12). DOI: 10.1073/pnas.2019893118

Table 1. Performance of the AI algorithm for predicting RDTs results with respect to human visual reading in the validation set (A), in the field study for reading antibodies

2 human visual reading in the validation set (A) , in the field study for reading antibodies
3 RDTs (Ab) (B) and in the field study when reading antigen RDTs (Ag) (C) .

³RDTs (Ab) (**B**) and in the field study when reading antigen RDTs (Ag) (**C**).

4

> **Figure 1**. Tiraspot system is composed of (1) a mobile app for test digitization and result recording, (2) an AI model for RDT result interpretation and (3) a web platform where all collected data can be visualized and allows for result corrections in the cases in which a discrepancy exists between AI and user interpretation.

